Silica Granules and Precipitation for IgG Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating immunoglobulin G (IgG) from blood products using affinity chromatography are complex and prone to fouling, limiting their utility in large-scale production due to the need for lengthy processing steps and high maintenance of chromatography columns.
Innovation Solution
The use of silica granules or powder combined with an organic salt to precipitate non-IgG proteins, allowing for a simplified upstream processing step that reduces fouling and enables direct application of the supernatant to a chromatography column, thereby simplifying the isolation of IgG.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If affinity chromatography is used to isolate IgG from blood products, then high purity IgG can be obtained, but the chromatography columns are prone to fouling which reduces capacity and requires lengthy cleaning steps
Solution Approach 1:
The patent applies preliminary precipitation steps using ammonium sulfate or organic solvents to remove contaminants and concentrate the blood product before applying it to the affinity chromatography column. This pre-treatment prevents fouling of the chromatography media by lipids, non-IgG proteins, and other blood constituents, thereby maintaining column capacity and reducing cleaning frequency while enabling high-purity IgG isolation.
2Manufacturing precision
If affinity chromatography is used to isolate IgG, then high purity can be achieved, but expensive affinity media capacity is greatly reduced due to fouling
Solution Approach 1:
The patent performs preliminary precipitation and clarification steps to remove fouling substances before the blood product contacts the affinity media. This protects the expensive affinity media from capacity loss due to fouling, allowing the media to maintain its binding capacity for IgG over multiple use cycles.
Solution Approach 2:
The patent introduces intermediary substances such as ammonium sulfate or organic solvents that act as precipitants to separate contaminants from the blood product. These intermediaries facilitate the removal of fouling agents before they can damage the affinity media, thereby preserving media capacity.
3Manufacturing precision
If conventional IgG isolation methods are used, then purification can be achieved, but lengthy and complex processing steps are required
Solution Approach 1:
The patent combines multiple functions into a single integrated process: precipitation, concentration, and partial purification are achieved in one step by adding ammonium sulfate or organic solvents to the blood product. This merged approach eliminates separate processing steps while still delivering high-purity IgG suitable for affinity chromatography.
Solution Approach 2:
The patent performs preliminary concentration and partial purification through precipitation before chromatography, which reduces the volume and complexity of the sample that needs to be processed through the full purification sequence. This pre-processing step shortens the overall processing time while maintaining high purity outcomes.
4Reliability
If convalescent plasma is administered directly, then passive immunity can be provided, but risks include transfusion reactions and acute lung injury
Solution Approach 1:
The patent extracts and isolates only the beneficial immunoglobulin G fraction from the blood product through affinity chromatography, separating it from other blood constituents that cause adverse reactions. This extraction process removes harmful substances while retaining the therapeutic antibodies, providing purified IgG that can be administered with reduced risk of transfusion reactions and acute lung injury.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces the economic impact of chromatography separation steps, enhances the availability of IgG for therapeutic purposes by preserving chromatography media capacity and reducing the need for extensive cleaning, allowing for more efficient and cost-effective large-scale production of IgG.
Implementation Method 1
contacting the blood product with a lipid/lipoprotein adsorbent material such as finely divided silica
Implementation Method 2
contacting the blood product with a lipid/lipoprotein adsorbent material such as finely divided silica (e.g., fumed silica) and/or other lipophilic and/or inert protein adsorbing materials... at a concentration that produces a first precipitate and a first supernatant
Data Source
AI summary
Compositions and methods are provided that simplify isolation of proteins of interest from serum or plasma. Finely divided silica or a similar lipid/lipoprotein binding solid is used in combination with a protein precipitating agent to generate a solution that includes the protein of interest and that can be applied to chromatography media without resulting in significant fouling of the media. The method is particularly suitable for isolation of immunoglobulin G.